All News
August 25, 2026
Moderna Cancer Vaccine Achieves Historic Phase 3 Success Paving Way for Personalized mRNA Oncology Revolution
moderna and merck have achieved a major breakthrough with a phase 3 trial of their personalized mRNA cancer vaccine intismeran autogene, showing it significantly reduces melanoma recurrence when used with keytruda. this marks the first late-stage success for any mRNA cancer vaccine and has sparked optimism for a new era in oncology by harnessing personalized immunotherapy. the positive results drove stock surges for both companies and led to analyst upgrades, though questions remain about long-term growth and commercial rollout across other cancer types. discover what sets this innovative approach apart and its implications for biotech, investing, and cancer treatment worldwide
Read more
All News
August 25, 2026
Tech Stocks Rally as Nvidia Earnings, Analyst Upgrades, and Alibaba Insider Buying Drive Market Momentum
Read more